Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice

Multiple variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have spread around the world, but the neutralizing effects of antibodies induced by the existing vaccines have declined, which highlights the importance of developing vaccines against mutant virus strains. In this stud...

Full description

Bibliographic Details
Main Authors: Juan Shi, Xiaoxiao Jin, Yan Ding, Xiaotao Liu, Anran Shen, Yandan Wu, Min Peng, Chuanlai Shen
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/9/12/1383
_version_ 1797500077360545792
author Juan Shi
Xiaoxiao Jin
Yan Ding
Xiaotao Liu
Anran Shen
Yandan Wu
Min Peng
Chuanlai Shen
author_facet Juan Shi
Xiaoxiao Jin
Yan Ding
Xiaotao Liu
Anran Shen
Yandan Wu
Min Peng
Chuanlai Shen
author_sort Juan Shi
collection DOAJ
description Multiple variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have spread around the world, but the neutralizing effects of antibodies induced by the existing vaccines have declined, which highlights the importance of developing vaccines against mutant virus strains. In this study, nine receptor-binding domain (RBD) proteins of the SARS-CoV-2 variants (B.1.1.7, B.1.351 and P.1 lineages) were constructed and fused with the Fc fragment of human IgG (RBD-Fc). These RBD-Fc proteins contained single or multiple amino acid substitutions at prevalent mutation points of spike protein, which enabled them to bind strongly to the polyclonal antibodies specific for wild-type RBD and to the recombinant human ACE2 protein. In the BALB/c, mice were immunized with the wild-type RBD-Fc protein first and boosted twice with the indicated mutant RBD-Fc proteins later. All mutant RBD-Fc proteins elicited high-level IgG antibodies and cross-neutralizing antibodies. The RBD-Fc proteins with multiple substitutions tended to induce higher antibody titers and neutralizing-antibody titers than the single-mutant RBD-Fc proteins. Meanwhile, both wild-type RBD-Fc protein and mutant RBD-Fc proteins induced significantly decreased neutralization capacity to the pseudovirus of B.1.351 and P.1 lineages than to the wild-type one. These data will facilitate the design and development of RBD-based subunit vaccines against SARS-COV-2 and its variants.
first_indexed 2024-03-10T03:56:40Z
format Article
id doaj.art-033632c36c354600b41fc91caf2723c4
institution Directory Open Access Journal
issn 2076-393X
language English
last_indexed 2024-03-10T03:56:40Z
publishDate 2021-11-01
publisher MDPI AG
record_format Article
series Vaccines
spelling doaj.art-033632c36c354600b41fc91caf2723c42023-11-23T10:53:37ZengMDPI AGVaccines2076-393X2021-11-01912138310.3390/vaccines9121383Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in MiceJuan Shi0Xiaoxiao Jin1Yan Ding2Xiaotao Liu3Anran Shen4Yandan Wu5Min Peng6Chuanlai Shen7Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing 210009, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing 210009, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing 210009, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing 210009, ChinaInstitute of Nephrology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing 210009, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing 210009, ChinaDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing 210009, ChinaMultiple variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have spread around the world, but the neutralizing effects of antibodies induced by the existing vaccines have declined, which highlights the importance of developing vaccines against mutant virus strains. In this study, nine receptor-binding domain (RBD) proteins of the SARS-CoV-2 variants (B.1.1.7, B.1.351 and P.1 lineages) were constructed and fused with the Fc fragment of human IgG (RBD-Fc). These RBD-Fc proteins contained single or multiple amino acid substitutions at prevalent mutation points of spike protein, which enabled them to bind strongly to the polyclonal antibodies specific for wild-type RBD and to the recombinant human ACE2 protein. In the BALB/c, mice were immunized with the wild-type RBD-Fc protein first and boosted twice with the indicated mutant RBD-Fc proteins later. All mutant RBD-Fc proteins elicited high-level IgG antibodies and cross-neutralizing antibodies. The RBD-Fc proteins with multiple substitutions tended to induce higher antibody titers and neutralizing-antibody titers than the single-mutant RBD-Fc proteins. Meanwhile, both wild-type RBD-Fc protein and mutant RBD-Fc proteins induced significantly decreased neutralization capacity to the pseudovirus of B.1.351 and P.1 lineages than to the wild-type one. These data will facilitate the design and development of RBD-based subunit vaccines against SARS-COV-2 and its variants.https://www.mdpi.com/2076-393X/9/12/1383SARS-CoV-2variantsspike proteinreceptor-binding domainimmunogenicityneutralizing antibodies
spellingShingle Juan Shi
Xiaoxiao Jin
Yan Ding
Xiaotao Liu
Anran Shen
Yandan Wu
Min Peng
Chuanlai Shen
Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
Vaccines
SARS-CoV-2
variants
spike protein
receptor-binding domain
immunogenicity
neutralizing antibodies
title Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
title_full Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
title_fullStr Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
title_full_unstemmed Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
title_short Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
title_sort receptor binding domain proteins of sars cov 2 variants elicited robust antibody responses cross reacting with wild type and mutant viruses in mice
topic SARS-CoV-2
variants
spike protein
receptor-binding domain
immunogenicity
neutralizing antibodies
url https://www.mdpi.com/2076-393X/9/12/1383
work_keys_str_mv AT juanshi receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice
AT xiaoxiaojin receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice
AT yanding receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice
AT xiaotaoliu receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice
AT anranshen receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice
AT yandanwu receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice
AT minpeng receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice
AT chuanlaishen receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice